NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









NuVision Biotherapies

NuVision Biotherapies

Private
NottinghamHealthcare & Life Scienceshttps://www.nu-vision.co.uk

Last Round

Early Funding

Feb 5, 2026

Total Funding Raised

$7.81M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

NuVision Biotherapies is a biotechnology company that develops and manufactures ophthalmic therapy products designed to offer surgeons new therapies for ocular care.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Biotechnology, Advanced Materials

Business Model

B2G

Customer Profile

Hardware Sales, Government Contracts, Freemium

AI Layer

Non-AI

Keywords

amniotic membrane therapyhuman amniotic membraneocular surface diseasesuture-free applicationregenerative medicineophthalmologycorneal repairbiotherapiesbandage contact lensdry eye disease treatmentocular traumamedical devicesroom-temperature stablebiotechclinical data registryuniversity spin-out

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

NuVision Biotherapies Comparables

Compare NuVision Biotherapies with similar companies based on industry and business-model similarity.

NuVision Biotherapies comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
BioTissue
84%
Merakris Therapeutics
78%
Corza Medical
76%

NuVision Biotherapies Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Early FundingFeb 5, 2026
VC RoundMar 8, 2023
VC RoundJul 15, 2021
SeedFeb 8, 2018
SeedJul 28, 2015

Key People

Founding team and executive leadership

Andy Hill

Chief Executive Officer

Executive Team

Tim Gray

Chief Financial Officer

Executive Team

NuVision Biotherapies Investors

Notable investors and investment history

NuVision Biotherapies investors
InvestorRounds
Pioneer GroupVC Round, Early Funding
British Business BankVC Round, Early Funding
Mercia VenturesEarly Funding
Mercia Asset ManagementVC Round
Mercia VenturesVC Round
The University of NottinghamSeed, VC Round, Early Funding

Market signals

Structured signals derived from secondary market and firmographic data.

  • Feb 5, 2026

    Raised $6.5M in early funding.

  • Jan 31, 2025

    Launched a new clinical product despite manufacturing challenges.

NuVision Biotherapies Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

NuVision Biotherapies Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about NuVision Biotherapies's valuation, stock price, and market status.

Firmographic Details

HeadquartersNottingham
Employee Range24
Year Founded2015
Last FundingFeb 5, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.